Compare Cognizant Technology Solutions Corp (CTSH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Zoetis Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.25 (market cap $27.03B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Cognizant Technology Solutions Corp and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Zoetis Inc for 70 Days on average.
| CTSH | ZTS | |
|---|---|---|
Market Cap | $27.03B | $30.20B |
Volume | 9,883,888 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $86.70 | $147.53 |
52-Week Low | $38.73 | $69.09 |
Typical Hold Time | 57 Days | 70 Days |
Enterprise Value | $28.08B | $37.76B |
Dividend Yield | 2.2% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.20, up 3.73% today, with a bullish technical signal from moving averages and support at $56. The stock shows solid fundamentals with a P/E of 12.88, net income margin of 10.26%, and consistent earnings beats in recent quarters. Recent news highlights AI-driven initiatives and strong employer recognition, supporting positive sentiment.
CTSH presents a favorable risk-reward profile with a consensus price target of $64.25 offering ~8.5% upside. Key opportunities include AI integration and stable cash flow, while risks involve IT spending pressures and competitive threats. Analyst consensus is balanced between Buy and Hold ratings, reflecting cautious optimism amid industry headwinds.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
